Soraprazan - Katairo

Drug Profile

Soraprazan - Katairo

Alternative Names: Remofuscin

Latest Information Update: 11 Jul 2016

Price : $50

At a glance

  • Originator Katairo
  • Class Antiulcers; Imidazoles; Naphthyridines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stargardt disease
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Stargardt disease

Most Recent Events

  • 11 Jul 2016 Chemical information added
  • 13 Nov 2013 Preclinical trials in Stargardt disease 1 in Germany (unspecified route)
  • 13 Nov 2013 Soraprazan - Katairo receives Orphan Drug status for Stargardt disease 1 in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top